ArticleClinical microbiology reviews2021
Erratum for Yahav et al., "New β-Lactam-β-Lactamase Inhibitor Combinations".
Article in Clinical microbiology reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Nacubactam and Its Metabolites on QTc Interval: A Pooled Analysis of Two Randomized Phase 1 Studies.Clinical and translational science · 2026Pooled it
- Pharmacokinetics and safety of EVER206, a novel polymyxin antimicrobial, in healthy Chinese subjects.Antimicrobial agents and chemotherapy · 2024Trial
- Dosing Regimen Optimization of Aztreonam/Avibactam According to Renal Function Stratification: A Population Pharmacokinetic-Guided Simulation Study.Antibiotics (Basel, Switzerland) · 2026Article
- Tandem amplification of theMicrobiology spectrum · 2026Article
- Model-Informed Ceftazidime-Avibactam Dosing Stratified by Renal Function and Renal Replacement Therapy Status in Critically Ill Patients: A Prospective Population Pharmacokinetic and Monte Carlo Simulation Study.Drug design, development and therapy · 2026Article
- Clinical efficacy, safety and pharmacokinetics of novel β-lactam/β-lactamase inhibitor combinations: a systematic review.JAC-antimicrobial resistance · 2025Review
- Carbapenem-resistant Enterobacterales bloodstream infections related to death in two Brazilian tertiary hospitals.BMC infectious diseases · 2025Article
- In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Private benefit of β-lactamase dictates selection dynamics of combination antibiotic treatment.Nature communications · 2024Article
- Article
- New Delhi Metallo-Beta-Lactamase Inhibitors: A Systematic Scoping Review.Journal of clinical medicine · 2024Article
- Ethynyl-substituted benzosiloxaboroles: the role of C(π)⋯B interactions in their crystal packing and use in Cu(i)-catalyzed 1,3-dipolar cycloaddition.RSC advances · 2024Article
- Clinical outcomes and risk factors for mortality in recipients with carbapenem-resistant gram-negative bacilli infections after kidney transplantation treated with ceftazidime-avibactam: a retrospective study.Frontiers in cellular and infection microbiology · 2024Observational
- In Vitro Activity of New β-Lactamase Inhibitor Combinations againstAntibiotics (Basel, Switzerland) · 2023Article
- Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales andJAC-antimicrobial resistance · 2023Article
- Synergistic Activity of Cefiderocol in Combination with Piperacillin-Tazobactam, Fosfomycin, Ampicillin-Sulbactam, Imipenem-Relebactam and Ceftazidime-Avibactam against Carbapenem-Resistant Gram-Negative Bacteria.Antibiotics (Basel, Switzerland) · 2023Article
- In vitro activity of cefepime/zidebactam and cefepime/taniborbactam against aztreonam/avibactam-resistant NDM-like-producing Escherichia coli clinical isolates.The Journal of antimicrobial chemotherapy · 2023Article
- Clinical Efficacy and Safety Evaluation of Ceftazidime-Avibactam in the Treatment ofInfection and drug resistance · 2023Article
- The threat of multidrug-resistant/extensively drug-resistant Gram-negative respiratory infections: another pandemic.European respiratory review : an official journal of the European Respiratory Society · 2022Article
- Clinical Risk Factors and Microbiological and Intestinal Characteristics of Carbapenemase-ProducingMicrobiology spectrum · 2022Article
Corrections and comments
- Erratum for
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.